• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Merck & Co (NY:MRK)

    145.31 -3.97 (-2.66%)
    Official Closing Price Updated: 7:00 PM EDT, Sep 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Merck & Co

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    29 30 Next >
    News headline image
    Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
    From Merck & Co.
    Via Business Wire
    News headline image
    U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV
    From Merck & Co., Inc.
    Via Business Wire
    MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
    Via Investor Brand Network
    Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
    Via Investor Brand Network
    MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
    Via Investor Brand Network
    News headline image
    Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Announces Fourth-Quarter 2026 Dividend
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
    From Merck & Co., Inc.
    Via Business Wire
    Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
    Via Investor Brand Network
    The Quest to Repair What Multiple Sclerosis Takes Away
    Via Investor Brand Network
    InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
    Via Investor Brand Network
    BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies
    Via Investor Brand Network
    Topics Artificial Intelligence
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    29 30 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.